Chinese vaccine maker known for its homegrown mRNA COVID-19 vaccine and other vaccines including HPV and pneumococcal.
Chinese vaccine maker known for its homegrown mRNA COVID-19 vaccine and other vaccines including HPV and pneumococcal.
Its main vaccines, the HPV and pneumococcal shots, sit mostly in China's self-paid market rather than the free national immunisation programme, so sales depend on parents choosing to buy. The mRNA COVID vaccine came from a joint effort with Abogen, in which Walvax is an investor.
In one line: A Chinese Moderna-adjacent vaccine developer.
Moat: narrow (IP / patents, regulatory licence). One of few Chinese developers with an in-house mRNA platform plus an established vaccine portfolio.
Headquarters: Kunming, China · Employees: 1,981
Size Walvax Biotechnology (300142.SZ) is a China Health Care company (Biotechnology) with a market value of $2.48B, the 963rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥10.58 on 18 Nov 2026.
Performance Over six months the shares fell 26.1%, against -8.9% for the median peer and -20.0% for the China market (cap-weighted) — 7th lowest of 21 in its peer set.
Growth Revenue fell 23.0% over the last twelve months (peer median +5.9%); the operating margin is 5.2% (peer median -25.4%).
Valuation It trades at 348.7× forward earnings against a peer median of 16.6× (most expensive of 6).
Price implies For today's price to make sense, revenue must grow about 30% a year for seven years (Req g). Recent delivered growth is -4%, so the hurdle is +33 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 5.7 points below its cost of capital (9.2% WACC).
Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.85B | CN¥2.41B | CN¥2.81B | CN¥4.09B | CN¥5.07B |
| Revenue growth | — | -14% | -31% | -19% | — |
| Gross profit | CN¥1.53B | CN¥1.66B | CN¥2.06B | CN¥3.41B | CN¥4.40B |
| EBITDA | n/a | CN¥482M | CN¥488M | CN¥987M | CN¥1.39B |
| Net income | CN¥21.8M | CN¥178M | CN¥142M | CN¥419M | CN¥729M |
| Free cash flow | CN¥391M | -CN¥15.2M | CN¥491M | CN¥195M | CN¥116M |
| Capital expenditure | CN¥376M | CN¥510M | CN¥550M | CN¥946M | CN¥1.09B |
| Total debt | CN¥1.41B | CN¥427M | CN¥512M | CN¥839M | CN¥522M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Walvax Biotechnology 300142.SZ | $2.48B | -26% | -23% | 5% | 348.7× | 29.5% |
| Chongqing Zhifei Biological Products 300122.SZ | $5.28B | -1% | -28% | -210% | n/a | -6.5% |
| Shenzhen Kangtai Biological Products 300601.SZ | $1.86B | -20% | -9% | 6% | 105.5× | 22.7% |
| Beijing Wantai Biological Pharmacy Enterprise 603392.SS | $4.20B | -43% | +8% | -35% | n/a | n/a |
| CanSino Biologics 688185.SS | $1.38B | 0% | +30% | -4% | 199.3× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300142.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -18.1% | -4.4% | 3rd lowest of 21 |
| 6-month return | -26.1% | -8.9% | 7th lowest of 21 |
| Distance from 52-week high | -37.6% | -30.1% | 10th lowest of 21 |
| Revenue growth (TTM) | -23.0% | +5.9% | 5th lowest of 19 |
| Operating margin | 5.2% | -25.4% | 6th highest of 18 |
| Forward P/E | 348.7× | 16.6× | most expensive of 6 |
| Growth the price implies (Req g, 7 yrs) | 29.5% | -0.6% | most demanding of 4 |
| Growth delivered (Del g) | -3.8% | +36.0% | lowest of 4 |
| Hurdle (Req g minus delivered) | +33.3 pp | -31.7 pp | most demanding of 4 |
| ROIC minus cost of capital | -5.7 pp | -11.6 pp | 6th highest of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Walvax Biotechnology 300142.SZ | China | $2.48B | -26% | -23% | 5% | 348.7× | 29.5% | -3.8% |
| Xiamen Amoytop Biotech 688278.SS | China | $2.56B | -27% | +18% | 27% | 15.0× | -0.6% | +36.0% |
| Xencor XNCR | United States | $2.58B | +204% | +34% | -73% | n/a | n/a | n/a |
| Hebei Changshan Biochemical Pharmaceutical 300255.SZ | China | $2.33B | -59% | 0% | -25% | n/a | n/a | n/a |
| MBX Biosciences MBX | United States | $2.65B | +70% | n/a | n/a | n/a | n/a | n/a |
| HLB 028300.KS | South Korea | $2.69B | -49% | +26% | -96% | n/a | n/a | n/a |
| Arcus Biosciences RCUS | United States | $2.27B | -34% | -58% | -475% | n/a | n/a | n/a |
| Sunshine Lake Pharma 6887.HK | Hong Kong | $2.72B | -7% | +20% | -3% | n/a | n/a | n/a |
| Lakefront Biotherapeutics LKFT.AS | Netherlands | $2.26B | +31% | +223% | 64% | n/a | n/a | n/a |
| Vimian VIMIAN.ST | Sweden | $2.26B | +51% | +8% | 19% | 38.4× | 13.4% | +44.5% |
| SKBS 302440.KS | South Korea | $2.25B | -12% | +11% | -23% | n/a | n/a | n/a |
| Pharvaris PHVS | United States | $2.21B | +7% | n/a | n/a | n/a | n/a | n/a |
| Zai Lab 9688.HK | Hong Kong | $2.79B | +23% | 0% | -63% | n/a | n/a | n/a |
| Bavarian Nordic A/S BAVA.CO | Denmark | $2.82B | +23% | -8% | 18% | 16.6× | -4.3% | +27.4% |
| Beam Therapeutics BEAM | United States | $2.17B | -22% | +163% | -268% | n/a | n/a | n/a |
| Celldex Therapeutics CLDX | United States | $2.16B | -11% | -94% | -211,685% | n/a | n/a | n/a |
| Zealand Pharma A/S ZEAL.CO | Denmark | $2.16B | -30% | -50% | 46% | 7.2× | n/a | n/a |
| XtalPi 2228.HK | Hong Kong | $2.87B | -34% | +4% | -127% | n/a | n/a | n/a |
| Palvella Therapeutics PVLA | United States | $2.14B | +27% | -100% | n/a | n/a | n/a | n/a |
| BGI Genomics 300676.SZ | China | $2.13B | -15% | 0% | -14% | 126.7× | n/a | n/a |
| Alamar Biosciences ALMR | United States | $2.12B | +51% | +195% | -42% | n/a | n/a | n/a |